Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody.
Biotechnol Rep (Amst)
; 42: e00844, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38881650
ABSTRACT
Dengue virus (DENV), transmitted by mosquitoes, is classified into four serotypes (DENV1-4) and typically causes mild, self-limiting symptoms upon initial infection. However, secondary infection can lead to severe symptoms due to antibody-dependent enhancement (ADE). To address this, anti-DENV antibodies are being developed with the goal of neutralizing infection without ADE activity. Previous attempts using a 54_hG1 antibody from CHO-K1 mammalian cells resulted in ADE induction, increasing viral infection. This study aimed to express the D54 monoclonal antibody in Nicotiana benthamiana. The plant-produced antibody had a similar neutralizing profile to the previous 54_hG1 antibody. Notably, the ADE activities of the plant-derived antibody were successfully eliminated, with no sign of viral induction. These findings suggest that N. benthamiana could be a source of therapeutic DENV antibodies. The method offers several advantages, including lower ADE, cost-effectiveness, simple facility requirements, scalability, and potential industrial-scale production in GMP facilities.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Biotechnol Rep (Amst)
Year:
2024
Document type:
Article
Affiliation country:
Thailand